UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 219

Sortiert nach

Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy

Clinical cancer research, 2017-01, Vol.23 (2), p.342-350

2017

Volltextzugriff (PDF)

Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression

Scientific reports, 2018-09, Vol.8 (1), p.13930-10, Article 13930

2018

Volltextzugriff (PDF)

Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002

Molecular therapy. Oncolytics, 2017-12, Vol.7, p.27-36

2017

Volltextzugriff (PDF)

Oncolytic virotherapy for pediatric malignancies: future prospects

Oncolytic virotherapy, 2016-01, Vol.5, p.73-80

2016

Volltextzugriff (PDF)

MB-41INTRAVENTRICULAR ONCOLYTIC ENGINEERED HERPES SIMPLEX VIRUS PROLONGS SURVIVAL AND REDUCES SPINAL METASTASES IN MICE BEARING HUMAN GROUP 3 MEDULLOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2016-06, Vol.18 (suppl 3), p.iii106.1-iii106

2016

Volltextzugriff (PDF)

IMMU-09. PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH CHILDHOOD BRAIN CANCER: INTERIM ANALYSIS OF THE GCC1949 STUDY (NCT04049669)

Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Suppl 4), p.0-0

2024

Volltextzugriff (PDF)

CTIM-32. FIRST-IN-CHILDREN PHASE 1 TRIAL OF INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS: ANALYSIS OF SAFETY, TOLERABILITY, AND 5-YEAR OUTCOME

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii68-vii68

2022

Volltextzugriff (PDF)

HGG-28. INTERIM ANALYSIS OF THE GCC1949 PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS

Neuro-oncology (Charlottesville, Va.), 2023-06, Vol.25 (Supplement_1), p.i46-i46

2023

Volltextzugriff (PDF)

IMMU-04. FIRST-IN-CHILDREN PHASE 1B STUDY USING THE IDO PATHWAY INHIBITOR INDOXIMOD IN COMBINATION WITH RADIATION AND CHEMOTHERAPY FOR CHILDREN WITH NEWLY DIAGNOSED DIPG (NCT02502708, NLG2105)

Neuro-oncology (Charlottesville, Va.), 2021-06, Vol.23 (Supplement_1), p.i27-i27

2021

Volltextzugriff (PDF)

PCM-21EXPRESSION OF IMMUNE CHECKPOINT PROTEINS IN PATIENT-DERIVED PEDIATRIC BRAIN TUMOR XENOGRAFTS

Neuro-oncology (Charlottesville, Va.), 2016-06, Vol.18 (suppl 3), p.iii143.4-iii143

2016

Volltextzugriff (PDF)

PCM-09COMPARISON OF THE SENSITIVITIES OF PEDIATRIC HIGH-GRADE BRAIN TUMOR VERSUS ADULT GLIOBLASTOMA XENOGRAFTS TO ENGINEERED ONCOLYTIC HERPES SIMPLEX VIROTHERAPY

Neuro-oncology (Charlottesville, Va.), 2016-06, Vol.18 (suppl 3), p.iii141.1-iii141

2016

Volltextzugriff (PDF)

Abstract LB200: Indoximod or ibrutinib/indoximod based clinical chemo-immunotherapy drives conversion of extra-tumoral circulating stem-like precursor CD8+ T cells into clonally expanded, rejuvenated effector cells

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB200-LB200

2023

Volltextzugriff (PDF)

Abstract CT004: Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT004-CT004

2018

Volltextzugriff (PDF)

TMOD-02. PEDIATRIC MEDULLOBLASTOMA XENOGRAFT GROWTH LOCATION TRANSFORMS TRANSCRIPTOMIC BUT NOT PHENOTYPIC PROFILES AND ALTERS SENSITIVITY TO RADIATION

Neuro-oncology (Charlottesville, Va.), 2017-06, Vol.19 (suppl_4), p.iv48-iv49

2017

Volltextzugriff (PDF)

IMMU-25. RADIO-IMMUNOTHERAPY USING THE IDO PATHWAY INHIBITOR INDOXIMOD FOR CHILDREN WITH NEWLY-DIAGNOSED DIPG

Neuro-oncology (Charlottesville, Va.), 2018-06, Vol.20 (suppl_2), p.i103-i104

2018

Volltextzugriff (PDF)

Insider Threat: Protecting the Enterprise from Sabotage, Spying, and Theft

Eric Cole, Sandra Ring

2005

Volltextzugriff (PDF)

Insider Threat

1, 2005

Volltextzugriff (PDF)

Forgive me, I'm bleeding

JAMA : the journal of the American Medical Association, 1998-02, Vol.279 (5), p.403

Ring, E W

1998

Volltextzugriff (PDF)

Cyber Spying Tracking Your Family's (Sometimes) Secret Online Lives

Eric Cole, Michael Nordfelt, Sandra Ring, Ted Fair

1, 2005

Volltextzugriff (PDF)

A DEMONSTRATION PROJECT ON FERTILITY CONTROL

RING, ABRAHAM ERIC

1965

Volltextzugriff (PDF)

Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps

Immunity (Cambridge, Mass.), 2015-05, Vol.42 (5), p.826-838

2015

Volltextzugriff (PDF)

SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity

Nature communications, 2023-03, Vol.14 (1), p.1299-1299, Article 1299

2023

Volltextzugriff (PDF)

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

The Journal of experimental medicine, 2020-12, Vol.217 (12)

2020

Volltextzugriff (PDF)

1 – 25 von 219

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(137)
Mit Volltextzugriff
(128)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy

Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression

Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002

Oncolytic virotherapy for pediatric malignancies: future prospects

MB-41INTRAVENTRICULAR ONCOLYTIC ENGINEERED HERPES SIMPLEX VIRUS PROLONGS SURVIVAL AND REDUCES SPINAL METASTASES IN MICE BEARING HUMAN GROUP 3 MEDULLOBLASTOMA

IMMU-09. PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH CHILDHOOD BRAIN CANCER: INTERIM ANALYSIS OF THE GCC1949 STUDY (NCT04049669)

CTIM-32. FIRST-IN-CHILDREN PHASE 1 TRIAL OF INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS: ANALYSIS OF SAFETY, TOLERABILITY, AND 5-YEAR OUTCOME

Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial

HGG-28. INTERIM ANALYSIS OF THE GCC1949 PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS

IMMU-04. FIRST-IN-CHILDREN PHASE 1B STUDY USING THE IDO PATHWAY INHIBITOR INDOXIMOD IN COMBINATION WITH RADIATION AND CHEMOTHERAPY FOR CHILDREN WITH NEWLY DIAGNOSED DIPG (NCT02502708, NLG2105)

PCM-21EXPRESSION OF IMMUNE CHECKPOINT PROTEINS IN PATIENT-DERIVED PEDIATRIC BRAIN TUMOR XENOGRAFTS

PCM-09COMPARISON OF THE SENSITIVITIES OF PEDIATRIC HIGH-GRADE BRAIN TUMOR VERSUS ADULT GLIOBLASTOMA XENOGRAFTS TO ENGINEERED ONCOLYTIC HERPES SIMPLEX VIROTHERAPY

Abstract LB200: Indoximod or ibrutinib/indoximod based clinical chemo-immunotherapy drives conversion of extra-tumoral circulating stem-like precursor CD8+ T cells into clonally expanded, rejuvenated effector cells

Abstract CT004: Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy

TMOD-02. PEDIATRIC MEDULLOBLASTOMA XENOGRAFT GROWTH LOCATION TRANSFORMS TRANSCRIPTOMIC BUT NOT PHENOTYPIC PROFILES AND ALTERS SENSITIVITY TO RADIATION

IMMU-25. RADIO-IMMUNOTHERAPY USING THE IDO PATHWAY INHIBITOR INDOXIMOD FOR CHILDREN WITH NEWLY-DIAGNOSED DIPG

Insider Threat: Protecting the Enterprise from Sabotage, Spying, and Theft

Insider Threat

Forgive me, I'm bleeding

Cyber Spying Tracking Your Family's (Sometimes) Secret Online Lives

A DEMONSTRATION PROJECT ON FERTILITY CONTROL

Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps

SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

Sex differences in immune responses that underlie COVID-19 disease outcomes

Suchergebnisse filtern